Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
Naaber P, et al.〔Lancet Reg Health Eur. 2021 Nov;10:100208〕（査読済み）
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On YM, et al.〔N Engl J Med. 2021 Oct 7;385(15):1393-1400〕（査読済み）
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
Choi A, et al.〔Nat Med. 2021 Nov;27(11):2025-2031〕（査読済み）
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 (Correspondence)
Falsey AR, et al.〔N Engl J Med. 2021 Oct 21;385(17):1627-1629〕（査読済み）
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Munro APS, et al.〔Lancet. 2021 Dec 2;398(10318):2258-2276〕（査読済み）
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Patalon T, et al.〔JAMA Intern Med. 2021 Nov 30;e217382〕（査読済み）
Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals（Research Letter）
Grunau B, et al.〔JAMA. 2021 Dec 3;e2121921〕（査読済み）
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Stuart ASV, et al.〔Lancet. 2021 Dec 6;S0140-6736(21)02718-5〕（査読済み）
BNT162b2 Vaccine Booster and Mortality Due to Covid-19
Arbel R, et al.〔N Engl J Med. 2021 Dec 23;385(26):2413-2420〕（査読済み）
Protection against Covid-19 by BNT162b2 Booster across Age Groups
Bar-On YM, et al.〔N Engl J Med. 2021 Dec 23;385(26):2421-2430〕（査読済み）
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines